Loading
A blood test approved with adagrasib to find the KRAS G12C mutation in lung cancer when a tissue biopsy is not possible.
Agilent's Resolution ctDx FIRST was approved by the FDA in December 2022 alongside adagrasib as a liquid biopsy companion diagnostic for KRAS G12C-mutant non-small-cell lung cancer, with tumour-profiling claims for other lung cancer genes. It is the second liquid comprehensive genomic profiling test with a companion claim after Guardant360 CDx and FoundationOne Liquid CDx. As with all plasma tests, a negative result should be followed by tissue testing.
Targeted NGS of plasma cell-free DNA covering lung cancer driver genes, with a companion claim for KRAS G12C. Connects to KRAS.
1.Resolution ctDx FIRST slips into a pocket on KRAS.
| Region | Year | Indication |
|---|---|---|
| US | 2022 | Companion diagnostic for adagrasib in KRAS G12C-mutant NSCLC (plasma) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Resolution ctDx FIRST" OR ABSTRACT:"Resolution ctDx FIRST") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Resolution ctDx FIRST, not a curated reading list.
Shares Companion diagnostics, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA), Non-small-cell lung cancer and the tag test.
Shares Agilent Technologies (Dako), Companion diagnostics, Non-small-cell lung cancer and the tag test.
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA), Non-small-cell lung cancer and the tag test.
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA) and the tag test.
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA), Non-small-cell lung cancer and the tag test.
Shares Companion diagnostics, KRAS and the tag test.
Shares Companion diagnostics, Circulating tumour DNA (ctDNA), KRAS, Liquid biopsy (ctDNA) and the tag test.
Shares Companion diagnostics, Non-small-cell lung cancer and the tag test.